Amneal Shareholders Overwhelmingly Approve Kashiv BioSciences Acquisition
AMRX has more than doubled off its 52-week low of $7.665.
Summary
Amneal Pharmaceuticals shareholders approved the acquisition of Kashiv BioSciences at a special meeting, with both the transaction and stock issuance proposals passing by wide margins. Closing is expected in the second half of 2026.
Key Events · M&A and Partnerships · AMRX
-
Shareholders Approve Kashiv Acquisition
Transaction Proposal approved with 138.3M votes for (99.5% of disinterested votes cast); Stock Issuance Proposal approved with 286.7M votes for (99.4% of votes cast).
-
Deal Terms: $375M Cash + 28.9M Shares
Amneal will acquire 100% of Kashiv BioSciences for $375M in cash and 28,942,108 shares of common stock, adding a portfolio of biosimilar candidates.
-
Closing Expected in H2 2026
The transaction is expected to close in the second half of 2026, subject to remaining regulatory approvals and other customary conditions.
-
Strong Shareholder Support
Over 90% of outstanding shares were represented at the meeting, with near-unanimous approval from disinterested stockholders, signaling broad investor backing for the deal.
Analysis · AMRX · Life Sciences
Amneal's shareholders voted decisively to approve the $375M cash-and-stock acquisition of Kashiv BioSciences, clearing a major hurdle. The transaction, which includes issuing 28.9M shares, is expected to close in the second half of 2026. The vote removes uncertainty around the deal, which expands Amneal's biosimilar pipeline and complements its recent positive clinical and regulatory momentum.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRX was trading at $18.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $7.67 to $19.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.